⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12474032 | 0.65 | — | — | |
| SCHEMBL28281416 | 0.65 | — | — | |
| SCHEMBL2016425 | 0.65 | — | — | |
| SCHEMBL692809 | 0.65 | — | — | |
| SCHEMBL4966817 | 0.62 | CA1 (0.30) | — | |
| SCHEMBL28007944 | 0.61 | — | — | |
| SCHEMBL4710658 | 0.60 | — | — | |
| SCHEMBL29536209 | 0.59 | — | — | |
| Hydrochloric Acid SCHEMBL3401475 | 0.58 | — | — | |
| Hydrochloric Acid SCHEMBL3401486 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137637-B1 | METHODS FOR REPROCESSING USED CATALYSTS | DR PLEY ENG & CONSULTING BUCHAREST SRL (RO) | 2018-10-31 | — | — | EP | claimed |
| WO-2024050725-A1 | METHODS OF PRODUCING 2, 3, 5, 6-ALKYL-1, 4-BENZOQUINONES | PTC THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| CN-116209446-A | 7- (piperidin-1-yl) -4H-pyrimido [1,2-B ] pyridazin-4-one derivatives as positive allosteric modulators of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2023-06-02 | — | — | CN | disclosed |
| WO-2022105845-A1 | GLUCOSIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京盈科瑞创新药物研究有限公司 | 2022-05-27 | — | — | WO | disclosed |
| CN-110291089-B | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death | 海帕瑞吉尼克斯股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-112189008-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-105658786-B | Method for producing adult liver progenitor cells | 普罗米迪拉生物科学公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-110612299-A | Pyrimidine derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| CN-105829334-B | Uracil nucleotides are like object and its preparation method and application | 江苏豪森药业集团有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-101300012-A | Diaminopyrimidine as P2X3 and P2x2/3 modulators | ROCHE PALO ALTO LLC (CH) | 2008-11-05 | — | — | CN | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1930135-A | As P2X3And P2X2/3Diaminopyrimidines as antagonists | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| CN-1696703-A | Biochemical analizer | FUJI PHOTO FILM CO LTD (JP) | 2005-11-16 | — | — | CN | disclosed |
| CN-1696697-A | Biochemical analizer | FUJI PHOTO FILM CO LTD (JP) | 2005-11-16 | — | — | CN | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
| EP-1214310-A1 | NOVEL PHOTOCHROMIC NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019812-A1 | NOVEL PHOTOCHROMIC NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 2001-03-22 | — | — | WO | disclosed |